{"nctId":"NCT01005888","briefTitle":"C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks","startDateStruct":{"date":"2005-03-14","type":"ACTUAL"},"conditions":["Hereditary Angioedema"],"count":26,"armGroups":[{"label":"C1INH-nf First, then Placebo","type":"EXPERIMENTAL","interventionNames":["Biological: C1 esterase inhibitor [human] (C1INH-nf)","Drug: Placebo (saline)"]},{"label":"Placebo First, then C1INH-nf","type":"EXPERIMENTAL","interventionNames":["Biological: C1 esterase inhibitor [human] (C1INH-nf)","Drug: Placebo (saline)"]}],"interventions":[{"name":"C1 esterase inhibitor [human] (C1INH-nf)","otherNames":[]},{"name":"Placebo (saline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented HAE\n* Normal C1q level\n* Relatively frequent angioedema attacks (at least 2 per month on average)\n\nExclusion Criteria:\n\n* Low C1q level\n* B-cell malignancy\n* Presence of anti-C1INH autoantibody\n* History of allergic reaction to C1INH or other blood products\n* Narcotic addiction\n* Current participation in any other investigational drug study or within the past 30 days\n* Participation in a C1 esterase inhibitor trial, or received blood or a blood product in the past 90 days\n* Pregnancy or lactation\n* Any clinically significant medical condition, such as renal failure, that in the opinion of the investigator would interfere with the subject's ability to participate in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Hereditary Angioedema (HAE) Attacks During Each Prophylactic Therapy Period","description":"An HAE attack was defined as the subject-reported indication of swelling at any location following a report of no swelling on the previous day. Analyses include observed attack counts and normalized attack counts (i.e., the number of attacks observed during each therapy period, normalized for the number of days the subject participated in that period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"5.43"},{"groupId":"OG001","value":"12.7","spread":"4.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"5.54"},{"groupId":"OG001","value":"12.7","spread":"4.65"}]}]}]},{"type":"SECONDARY","title":"Number of Subject Withdrawals During Each Prophylactic Therapy Period","description":"At the end of each therapy period, each subject was assigned a yes/no drop-out status. A drop-out was defined as a subject who did not have a Week 12 visit record.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Severity of HAE Attacks During Each Prophylactic Therapy Period","description":"All attacks in each therapy period were assigned a value of 1 (mild), 2 (moderate), or 3 (severe). Attack severity was considered the highest value assigned by the subject to any swelling location during the attack. Average severity was set to 0 if there was no attack in a period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"0.85"},{"groupId":"OG001","value":"1.9","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Average Duration of HAE Attacks During Each Prophylactic Therapy Period","description":"The duration of an attack was measured from the first report of swelling at any one of the five locations (abdominal, genitourinary, facial, respiratory \\[including laryngeal\\], or extremity) until the first subsequent report of \"no swelling\" at all five locations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.13"},{"groupId":"OG001","value":"3.4","spread":"1.39"}]}]}]},{"type":"SECONDARY","title":"Number of Open-label C1INH-nf Infusions Required During Each Prophylactic Therapy Period","description":"The study design allowed for subjects to be treated with open-label C1INH-nf for laryngeal angioedema, if deemed necessary by the investigator, or prior to emergency surgical procedures.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"8.66"},{"groupId":"OG001","value":"15.4","spread":"8.41"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Total Number of Days of Swelling During Each Prophylactic Therapy Period","description":"A day of swelling was defined as a day that a subject reported swelling at any of the five locations (abdominal, genitourinary, facial, respiratory \\[including laryngeal\\], or extremity).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"10.73"},{"groupId":"OG001","value":"29.6","spread":"16.90"}]}]}]},{"type":"SECONDARY","title":"Antigenic C1 Inhibitor (C1INH) Serum Levels","description":"Change in antigenic C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"15.08"},{"groupId":"OG001","value":"14.2","spread":"14.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"3.70"},{"groupId":"OG001","value":"-0.1","spread":"2.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8","spread":"5.08"},{"groupId":"OG001","value":"0.1","spread":"5.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"5.62"},{"groupId":"OG001","value":"-0.3","spread":"3.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"5.93"},{"groupId":"OG001","value":"1.1","spread":"5.98"}]}]}]},{"type":"SECONDARY","title":"Functional C1INH Serum Levels","description":"Percent change in functional C1INH serum levels from pre-infusion to 1 hour post-infusion at Visit 1 and Weeks 4, 8, and 12. Pre-infusion samples obtained at Visit 1 of each therapy period (i.e., baseline) were used to determine change at 1 hour post-infusion for all visits. Functional C1INH serum levels are expressed as a percent of total detectable C1INH (i.e., functional C1INH/total detectable C1INH).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":"17.21"},{"groupId":"OG001","value":"31.7","spread":"21.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":"18.95"},{"groupId":"OG001","value":"-2.4","spread":"9.41"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6","spread":"17.62"},{"groupId":"OG001","value":"5.3","spread":"26.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"19.08"},{"groupId":"OG001","value":"5.4","spread":"15.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9","spread":"21.07"},{"groupId":"OG001","value":"0.8","spread":"23.92"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Cough","Pruritus","Rash","Chest discomfort","Pyrexia"]}}}